Amundi Increases Holdings in Intuitive Surgical, Inc. $ISRG

Key Points

• Amundi increased its holdings in Intuitive Surgical, Inc. by 7.6%, owning 3,303,194 shares valued at approximately $1.63 billion, making it the company's 25th largest holding.
• Multiple institutional investors, including Chilton Capital Management and TD Capital Management, have significantly boosted their stakes, highlighting a strong interest in Intuitive Surgical, which is now 83.64% owned by institutional investors.
• Despite positive earnings reports and a Moderate Buy rating from analysts, including a target price increase by Piper Sandler, Intuitive Surgical's stock faces mixed ratings with some firms issuing a sell rating.

Amundi lifted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 7.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,303,194 shares of the medical equipment provider's stock after acquiring an additional 233,108 shares during the period. Intuitive Surgical accounts for about 0.6% of Amundi's portfolio, making the stock its 25th biggest holding. Amundi owned approximately 0.92% of Intuitive Surgical worth $1,633,877,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Chilton Capital Management LLC boosted its stake in Intuitive Surgical by 614.3% in the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares during the period. Global Financial Private Client LLC lifted its holdings in shares of Intuitive Surgical by 253.3% in the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after buying an additional 38 shares in the last quarter. Elite Financial Inc. bought a new position in shares of Intuitive Surgical during the first quarter worth $26,000. LFA Lugano Financial Advisors SA bought a new position in shares of Intuitive Surgical during the first quarter worth $30,000. Finally, TD Capital Management LLC grew its stake in Intuitive Surgical by 300.0% during the first quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 45 shares in the last quarter. Institutional investors own 83.64% of the company's stock.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the transaction, the executive vice president owned 353 shares in the company, valued at $173,845.44. The trade was a 92.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Mark Brosius sold 216 shares of the stock in a transaction on Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the sale, the senior vice president directly owned 907 shares in the company, valued at approximately $510,740.77. This represents a 19.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,769 shares of company stock valued at $21,532,536 over the last three months. 0.70% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ISRG. Zacks Research downgraded shares of Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 20th. Erste Group Bank reaffirmed a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. BTIG Research boosted their target price on Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Piper Sandler restated an "overweight" rating and set a $595.00 price target (up previously from $575.00) on shares of Intuitive Surgical in a report on Wednesday, July 23rd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "sell" rating on shares of Intuitive Surgical in a report on Friday, August 22nd. Thirteen equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Intuitive Surgical has an average rating of "Moderate Buy" and a consensus price target of $595.95.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $469.07 on Wednesday. Intuitive Surgical, Inc. has a 1-year low of $425.00 and a 1-year high of $616.00. The business's 50 day moving average is $498.54 and its two-hundred day moving average is $515.81. The stock has a market capitalization of $168.15 billion, a P/E ratio of 65.42, a PEG ratio of 4.96 and a beta of 1.61.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. The firm had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The company's quarterly revenue was up 21.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.78 EPS. As a group, equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.